The U.S. FDA has granted orphan drug designation to Eisai's (OTCPK:ESALF) Lenvima (lenvatinib) for esophageal cancer. The ...

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

which is also used to treat endometrial carcinoma without MSI-H or dMMR in combination with Eisai's multikinase inhibitor Lenvima (lenvatinib), and as a monotherapy and combination therapy for PD ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Exelixis Inc (EXEL) reports robust Q3 2024 financials, raises full-year guidance, and strengthens its market position through ...